Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome. A single center experience

Japanese Heart Journal

Volumn 43, Issue 5, 2002, Pages 433-442

  Özdemir, Murat ^a   Erdem, Güliz ^a   Türkoǧlu, Sedat ^a   Cemri, Mustafa ^a   Timurkaynak, Timur ^a   Boyaci, Bülent ^a   Yalçin, Ridvan ^a   Çengel, Atiye ^a   Dörtlemez, Övsev ^a   Dörtlemez, Halis ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; Dalteparin; Enoxaparin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; TICLOPIDINE; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECCHYMOSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATURIA; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; MIDDLE AGED;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 18744378015     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.43.433     Document Type: Article

References (24)

1. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988; 319: 1105-11.
2. Braunwald E, Jones RH, Mark DB, et al. Diagnosis and managing unstable angina: Agency for Health Care Policy and Research. Circulation 1994; 90: 613-22.
3. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-5.
4. Fox KAA, Antman EM. Treatment options in unstable angina: a clinical update. Eur Heart J 1998; 19 (Suppl K): K8-K10.
5. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
6. Warkentin TE, Levine MN, Hirsh J, et al. HeHoparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
7. Splinder SA, Nawarskas JJ. Low molecular weight heparins for acute coronary syndromes. Ann Pharmacother 1998; 32: 103-10.
8. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-8.
9. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593-601.
11. Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
12. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-8.
13. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (Fraxiparine in Ischemic Syndrome). Eur Heart J 1999; 20: 1553-62.
14. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 338: 688-98.
15. Zed PJ, Tisdale JE, Borzak S. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 1999; 159: 1849-57.
16. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome : Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 1699-712.
17. Turpie AGG. Pharmacology of the low-molecular-weight heparins. Am Heart J 1998; 135: S329-35.
18. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6: S57-S64.
19. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803.
20. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52.
21. Montelascot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease : beneficial effects of enoxaparin. Circulation 1998; 98: 294-9.
22. Antman EM, Handin R. Low-molecular-weight heparins : an intriguing new twist with profound implications. Circulation 1998; 98: 287-9.
23. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins : pharmacologic profile and product differentiation. Am J Cardiol 1998; 82 (suppl 5B): 3L-10L.
24. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40.